Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
Study sponsor: TG Therapeutics, Inc. · TGTX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-06-10Actual
Enrollment · participants51Actual
Source updated2024-07-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.